H-1B sponsorship profile: RAPT Therapeutics, Inc (Formerly FLX Bio, Inc). Across U.S. Department of Labor LCA disclosures, RAPT Therapeutics, Inc (Formerly FLX Bio, Inc) filed 8 Labor Condition Applications covering 8 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (8 certified of 8 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on RAPT Therapeutics, Inc (Formerly FLX Bio, Inc)’s H-1B petitions range from $88,700 at the low end to $250,000 at the high end, with a petition-weighted average of $185,146. That range reflects the mix of occupations the company sponsors, led by Regulatory Operations Director (2 petitions at $222,602 avg), followed by Senior Manager, Regulatory Affairs and Senior Manager, Clinical Data Management Operations. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. RAPT Therapeutics, Inc (Formerly FLX Bio, Inc) is headquartered in South San Francisco, CA under NAICS code 541714, and places H-1B workers across 2 states, most heavily in CA, MA. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where RAPT Therapeutics, Inc (Formerly FLX Bio, Inc) ranks. By H-1B petition volume, RAPT Therapeutics, Inc (Formerly FLX Bio, Inc) is #19,368 of 119,880 employers nationally and #3,115 of 22,893 employers headquartered in CA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.